Tesofensine vs PT-141
Head-to-head comparison of Tesofensine (Tesofensine (NS2330)) and PT-141 (Bremelanotide (Melanocortin Receptor Agonist)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Tesofensine | PT-141 |
|---|---|---|
| Category | Weight Management | Performance |
| Full Name | Tesofensine (NS2330) | Bremelanotide (Melanocortin Receptor Agonist) |
| Molecular Weight | 426.52 g/mol | 1,025.2 Da |
| Half-Life | ~200-300 hours | ~2.7 hours |
| Amino Acids | Small molecule | 7 |
| Typical Dose | — | 1.75 mg |
| Route | — | SC |
| Purity | >98% | — |
| Studies Count | 35 | 178 |
| Research Status | Phase III Clinical Trials | FDA Approved |
Tesofensine Benefits
- ✓Potent appetite suppression, increased metabolic rate, enhanced thermogenesis, improved mood during dieting, reduces food reward-seeking behavior
PT-141 Benefits
- ✓Enhances sexual desire and arousal
- ✓Works through CNS (not vascular)
- ✓FDA-approved for HSDD
- ✓Effective for both men and women
- ✓Does not require sexual stimulation to work
Tesofensine Dosing
Clinical doses: 0.25-1.0 mg orally once daily. Research typically uses 0.5 mg. Extremely long half-life (8-13 days) means steady-state in 7-10 days.
PT-141 Dosing
Standard: 1.75 mg SC, 45 min before activity|Max frequency: Once every 24 hours|Max: 8 doses per month|Men (off-label): 1-2 mg SC as needed
Tesofensine Side Effects
- ⚠Dry mouth, insomnia, constipation, increased heart rate, elevated blood pressure. Not recommended with uncontrolled hypertension.
PT-141 Side Effects
- ⚠Common: Nausea (40%), flushing, headache, injection site reactions
- ⚠Moderate: Elevated blood pressure (transient), fatigue
- ⚠Serious: Focal hyperpigmentation with repeated use
- ⚠Contraindications: Uncontrolled hypertension, cardiovascular disease
Research Overview
Tesofensine
Phase II trials showed 12.8 kg average weight loss at 1.0 mg dose over 6 months. Simultaneously inhibits reuptake of norepinephrine, dopamine, and serotonin, producing appetite suppression and increased thermogenesis.
PT-141
PT-141 has robust clinical evidence including multiple Phase III trials. FDA-approved in 2019. Unique mechanism of action through melanocortin-4 receptors in the brain. Well-characterized safety and efficacy profile.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.